Countries like Saudi Arabia and Brazil are building their biotech sectors by offering a critical asset Western pharma companies struggle to find: diverse patient populations. Access to these demographics for clinical trials provides invaluable data, making these regions strategic partners for global drug development.
Former industrial cities are experiencing a renaissance as potential biotech hubs. They offer a unique combination of established universities, a history of manufacturing, and, crucially, low property and living costs left over from de-industrialization, creating an attractive environment for startups.
Cities vying for biotech hub status can experience rapid real estate development that outpaces demand during industry downturns. This leads to high vacancy rates and cheaper lab space, a boon for small biotechs but a risk for developers and a warning for other aspiring cities.
Industry insiders believe that US attempts to limit investment or clinical trials in China will not slow its biotech growth. Any vacuum created by US withdrawal is expected to be immediately filled by capital and partnerships from Europe and other Chinese firms, rendering the sanctions ineffective.
Basel, with fewer than 200,000 residents, thrives as a global biotech hub by drawing talent from neighboring France and Germany. Its key advantage is serving as a nexus for navigating Europe's complex, country-specific regulatory landscapes, making it an attractive base for life science companies.